Drug Trial Radar · NCT07855016
A Phase II Study of TT-01488 Tablets in Combination With Anti-CD20 Monoclonal Antibody Therapy in Patients With Mantle Cell Lymphoma
Last checked: Nov 19, 2026Latest source record: Oct 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
188
Planned (sponsor's estimate)
Start
Oct 10, 2026
Primary completion
Oct 10, 2029
Study completion Oct 10, 2029
Sponsor
- Lead sponsor
- TransThera Sciences (Nanjing), Inc.Industry
- Sponsor type
- Industry
- First posted
- Oct 2, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter, open-label, phase II study evaluating TT-01488 in combination with different anti-CD20 monoclonal antibody-containing regimens for the treatment of treatment-naïve mantle cell lymphoma (MCL).
Conditions
- Mantle Cell Lymphoma (MCL)
Interventions
TT-01488 TabletsDrug
Oral
RituximabDrug
Intravenous Injection (IV)
Immunomodulatory AgentDrug
Oral
BCL2 InhibitorDrug
Oral
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part A Dose-limiting toxicity (DLT)Time frame: At the end of Cycle 1 (each cycle is 28 days)
- Part B Complete Response Rate (CRR) After 6 Cycles of Induction TherapyTime frame: After 6 cycles of induction therapy (each cycle is 28 days)
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, China
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.